CodeBlue urges Malaysian MPs to vote for tobacco control bill

Jul.18.2022
CodeBlue urges Malaysian MPs to vote for tobacco control bill
Malaysian health NGO, CodeBlue, urges lawmakers to support the Tobacco and Smoking Control Bill to ban cigarettes for those born after 2005.

CodeBlue, a non-profit health organization in Malaysia, is urging lawmakers to vote in support of the "Tobacco and Smoking Control Bill," which would prohibit individuals born after 2005 from purchasing and using cigarettes. Here is the full statement.


The crucial "Tobacco and Smoking Control Act" will be submitted to Parliament this week, which will have an impact on the health and social welfare of our future generations. It is crucial that all members of Parliament fully understand these issues and support this important legislation.


It is important to note that this bill does not restrict smoking among adults, but rather aims to prohibit the sale and use of cigarettes and e-cigarette products to all children born after 2005 (those who will turn 18 in 2023).


Smoking is a rapidly growing epidemic among our children. The 2019 national health and disease rate survey provides us with national data on adolescent smoking behavior. The data is alarming for children aged 15 to 19, as it shows a significant increase in smoking rates.


At present, there are 303,800 smokers, accounting for 11.6% of the population.


A total of 196,000 individuals, which is equivalent to 7.5% of the population, are currently using e-cigarettes.


15.6% of teenagers aged 15 to 19 are currently using tobacco products.


It is anticipated that since the investigation, there has been a significant increase in the number of adolescents who have started using electronic cigarettes in recent years. As pediatricians, we are aware that many young children are drawn to using electronic cigarette products due to their appealing flavors and stylish devices, as well as the desire to appear "cool".


Teenagers smoking electronic cigarettes and becoming addicted can be seen throughout the country. It is widely recognized that most smokers develop their habit in their teens, and smoking e-cigarettes only makes it easier to develop addiction.


Worrying statistics have emerged from the Malaysian National Tobacco and E-cigarette Survey among Youth (TECMA), which shows that 9.1% of Malaysian youths aged 10 to 19 currently use e-cigarettes, with at least 600,000 children included in this group. Among these children, half started using e-cigarettes before the age of 14.


Smoking addiction is extremely difficult to overcome. Some users will gradually turn to more addictive and harmful drugs.


We urge our congressional representatives to consider the health and well-being of all of our children. Please vote in favor of the Tobacco Control Act. The impact of eliminating a major source of social ills and reducing the long-term health problems and death tolls cannot be overstated.


Voting in favor of this bill is a vote in support of investing in the current and future health and well-being of our children.


Voting in favor of the bill represents a vote of hope for all families whose children are no longer addicted to drugs or e-cigarettes.


Voting in favor of the bill is a vote in support of our healthcare system to alleviate the burden of major illnesses.


Dr. Amar-Singh HSS is a pediatric consultant.


Dr. Selva Kumar is a pediatric consultant and the president of the Malaysian Pediatric Association (MPA).


Dr. Musa Mohd Nordin, pediatric consultant.


Dr. Zulkifli Ismail, Pediatric Consultant.


Dr. Thiyagar Nadarajaw is a pediatric consultant and vice president of the Malaysian Adolescent Health Association (MAAH).


Please provide context and the original text to be translated.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
China exported $979 million of vape-related products in August 2026, up 3.3% from a year earlier but down 6.4% from July. The UK replaced the U.S. as the main source of growth: UK-bound shipments jumped 51.4% to a 2026 high of $177 million, while exports to the U.S. fell 12.4% to $339 million. Shipments to markets outside the U.S. increased 14.2%, broadening growth beyond the market that had driven July’s rebound.
News
Sep.23 by 2Firsts Perspectives
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Philip Morris International (PMI) is expanding the international footprint of BONDS by IQOS, its lower-priced heated tobacco platform. The company's third-quarter 2026 SEC filing shows that BONDS devices and BLENDS tobacco sticks were available in 15 markets at the end of September, up from eight at the end of June. In November, PMI announced plans to extend sales from three to 17 Japanese prefectures and introduced BONDS in Spain and Morocco. The platform uses ROUNDHEAT external heating technology and proprietary tobacco sticks, separate from the IQOS ILUMA system. In Japan, BONDS retails for ¥2,980, approximately 25% below ILUMA i ONE, while BLENDS costs ¥570 per pack. PMI management says BONDS targets cigarette smokers who have not adopted heated tobacco. Separate sales and revenue figures remain undisclosed.
company
Nov.06
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22